Gland Pharma Ltd - 543245 - Disclosure Under Regulation 23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('SEBI LODR'') - Details Of Related Party Transactions
The Board of Directors of the Company has considered and taken note of the inadvertent delay of Three days in filing the disclosure of Related party transactions for the Half-year ended March 31, 2021 matter. Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Meeting with Goldman Sachs Asset Management Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Meeting with Thornburg Investment Management and Buena Vista fund Management
Q2 growth helps Gland Pharma but margins disappoint
Analysts attribute the underwhelming gross margins to adverse product mix and an increase in cost pressures for the drugmaker Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Monitoring Agency Report for the Quarter ending September 30, 2021 Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication of Unaudited Financial Results for the Quarter and Half Year ended Sep 30, 2021
Earnings Call for Q2FY22 of Gland Pharma
Conference Call with Gland Pharma Management and Analysts on Q2FY22 Performance and Outlook. Listen to the full earnings transcript.
Gland Pharma to announce four complex injectables during FY22; Q2 profit rises 38%
Announcing the Q2 FY22 financial results, CEO Srinivas Sadu stated that Gland Pharma is on track to make four complex injectable filing during the current financial year Q2FY22 Quarterly Result Announced for Gland Pharma Ltd.
Highlights: Revenue from operations during the second quarter of financial year 2022 grew by 30% as compared to corresponding quarter of the previous year. The Company maintained a healthy EBITDA margin of 38% and PAT margin of 27% during the quarter. Revenue from operations for the six months ended September 30, 2021 grew by 30% as compared to the corresponding period of previous year. The growth in revenue was on account of launch of new products# and growth in existing products. Our key markets, US, Canada, Europe and Australia registered a growth of 25% and accounted for 62% of our revenue during Q2FY22. The strength of our wide portfolio helped us to sustain growth amidst changing market demand as COVID-19 hospitalizations declined. Rest of the World markets have seen a robust growth of 59% in line with our increased focus on geographic expansion. Thisis driven by increased penetration by forming new partnershipsin various countries. India accounted for 17% of Q2FY22 revenue and witnessed a 19% Y-o-Y growth for the quarter. Commenting on the results, Mr. Srinivas Sadu, MD & CEO of Gland Pharma said “We delivered a strong performance this quarter Q2 FY22, with a revenue of Rs 10,805 million, which is a y-o-y revenue growth of 30%. With a PAT of Rs 3,021 million, we saw a y-o-y PAT growth of 38% for the quarter. We continue to focus on revenue diversification across geographies, which is helping us further improve our manufacturing efficiencies because of benefits from scale as well as de-risking the business. With declining COVID-19 hospitalizations, we observed a shift in product mix. Our wide therapeutic portfolio helped us to sustain growth despite changing market demand. Our rich R&D; pipeline is helping us maintain strong momentum of new product launches. We are on track to make four complex injectable filings in this financial year.” Result PDF Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Investor Presentation
Earnings Presentation on the Unaudited Financial Results for the Quarter and half year ended September 30, 2021